Clinical trial repurposes cancer drug for treatment of vascular malformations wisc.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wisc.edu Daily Mail and Mail on Sunday newspapers.
Target RWE Research Presented at DDW 2021 Shows High Rates of Biologic Combination Therapy and Previous Biologic Exposure in IBD Population
Poster of Distinction Award Granted to TARGET-IBD Research
News provided by
Share this article
Share this article
DURHAM, N.C., May 23, 2021 /PRNewswire/ Research presented today at Digestive Disease Week (DDW) 2021 evaluated the prevalence and predictors of immunomodulator use as concomitant therapy with two commonly prescribed biologics, vedolizumab (Entyvio) or ustekinumab (Stelara), in patients with inflammatory bowel disease (IBD). Data from Target RWE s TARGET-IBD large longitudinal cohort
Immunomodulators are Commonly Used as Concomitant Therapy with Vedolizumab or Ustekinumab: TARGET-IBD Real World Cohort was selected for the Poster of Distinction Award.
Mittelohrentzündung: Lohnt sich ein Paukenröhrchen oder lieber Antibiotik pharmazeutische-zeitung.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmazeutische-zeitung.de Daily Mail and Mail on Sunday newspapers.
AI predicts lung cancer risk eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.